HUM heads into its July 29 earnings report with options markets flashing the most defensive signal in nearly a year.
The clearest sign of investor caution is in the options market. The put/call ratio jumped to 1.03 on Friday — almost 2.8 standard deviations above its 20-day average of 0.94, and the highest reading in the past 52 weeks outside of a single outlier in June. That's a sharp departure from the mild, call-skewed positioning that has prevailed for most of the past two months, and it landed on the same day the stock fell 1.3% to $389.32. The one-week decline of 2.7% follows an 8.4% monthly rally, so the defensive pivot in options arrives after a meaningful run — investors appear to be locking in some protection rather than chasing the move higher.
Short interest, by contrast, tells a less alarming story. Bears have been covering aggressively: SI as a percentage of free float has collapsed from roughly 5–6% in mid-June to 3.2% today, a 38% drop in one month. The lending market confirms there is no squeeze or crowding pressure — borrow availability is extraordinarily loose at over 8,000%, meaning shares to borrow remain plentiful relative to the current short base. Borrowing costs are also negligible at 0.51%. The short score of 33.6 has barely moved all month. Altogether, the lending market suggests that whatever nervousness options traders are expressing, it is not being amplified by a crowded short position.
The bull and bear cases for the July print are unusually far apart. Bulls point to the 500 basis-point improvement in Group Medicare Advantage margins — evidence that contract renegotiations are working — plus 16% revenue growth at CenterWell's pharmacy business. Momentum has been the dominant force driving the stock's 54% YTD rally, and the recent wave of analyst upgrades reinforces the optimism: Wells Fargo upgraded to Overweight last week with a $502 target, while TD Cowen and Truist both lifted targets sharply even while staying at Hold. The consensus mean target of $348 sits below the current price of $389, but that gap reflects how quickly the stock has moved — several recent targets remain in the $300–$415 range and likely do not fully reflect the pace of the recovery. Bears are focused on the estimated $3.5 billion Medicare Advantage Star ratings headwind, which could weigh roughly $22 on 2026 EPS, combined with the structural pressures of inadequate reimbursement rates and intensifying competition. The EPS momentum factor score of 90 out of 100 speaks to how rapidly estimates have risen — but it also raises the bar for what the print needs to deliver.
Pzena Investment Management added nearly 1.4 million shares as of late May, making it the fifth-largest institutional holder at 4.6% of shares. Dodge & Cox remains the largest holder at 9.5% and added modestly in the most recent quarter. Within the managed-care peer group, UNH and ELV dipped less than 1.5% on the week, while CNC fell 4.6% — HUM's 2.7% weekly decline places it in the middle of a broadly soft group. The July 29 print is therefore less about the direction of Medicare Advantage than about whether Humana can demonstrate that the margin recovery is durable enough to justify a price that has already moved well past consensus targets.
See the live data behind this article on ORTEX.
Open HUM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
